Combined T and B Cell Immunodeficiencies

  • Francisco A. Bonilla
  • Isil B. Barlan
  • Elif Aydiner
  • Waleed Al-Herz
  • Martha M. Eibl
  • Teresa Espanol
  • Andrea Martín
  • László Maródi
  • Shabnam Pourhamdi
  • Pere Soler-Palacín
  • Hermann M. Wolf
  • Asghar Aghamohammadi


The immune system is divided into humoral and cellular mechanisms. B cells are known for their role in humoral immunity by secreting antibodies against various pathogens, and T cells are responsible for cell-mediated immunity by killing intracellular organisms. T cells are also necessary in the maturation of B cells into antibody secreting plasma cells.


Bone Marrow Transplantation Hematopoietic Stem Cell Transplant Correct Answer Absolute Count Primary Immunodeficiency Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hitzig WH, Biro Z, Bosch H, Huser HJ (1958) Agammaglobulinemia & alymphocytosis with atrophy of lymphatic tissue. Helv Paediatr Acta 13(6):551–585PubMedGoogle Scholar
  2. 2.
    Stiehm ER (1996) Immunologic disorders in infants and children, 4th edn. W.B. Saunders Co, PhiladelphiaGoogle Scholar
  3. 3.
    Gatti RA, Good RA (1971) Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28(1):89–98PubMedCrossRefGoogle Scholar
  4. 4.
    Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, Kobrynski LJ, Levinson AI, Mazer B, Nelson RP Jr, Orange JS, Routes JM, Shearer WT, Sorensen RU (2005) Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94(5 Suppl 1):S1–S63PubMedCrossRefGoogle Scholar
  5. 5.
    Bonilla FA (2008) Interpretation of lymphocyte proliferation tests. Ann Allergy Asthma Immunol 101(1):101–104PubMedCrossRefGoogle Scholar
  6. 6.
    Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME (2003) The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82(6):373–384CrossRefGoogle Scholar
  7. 7.
    Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, Wara DW, Douglas SD, Luzuriaga K, McFarland EJ, Yogev R, Rathore MH, Levy W, Graham BL, Spector SA (2003) Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 112(5):973–980PubMedCrossRefGoogle Scholar
  8. 8.
    van Gent R, van Tilburg CM, Nibbelke EE, Otto SA, Gaiser JF, Janssens-Korpela PL, Sanders EA, Borghans JA, Wulffraat NM, Bierings MB, Bloem AC, Tesselaar K (2009) Refined characterization and reference values of the pediatric T- and B-cell compartments. Clin Immunol 133(1):95–107PubMedCrossRefGoogle Scholar
  9. 9.
    Moallem HJ, Taningo G, Jiang CK, Hirschhorn R, Fikrig S (2002) Purine nucleoside phosphorylase deficiency: a new case report and identification of two novel mutations (Gly156A1a and Val217Ile), only one of which (Gly156A1a) is deleterious. Clin Immunol 105(1):75–80PubMedCrossRefGoogle Scholar
  10. 10.
    Aytekin C, Dogu F, Tanir G, Guloglu D, Santisteban I, Hershfield MS, Ikinciogullari A (2010) Purine nucleoside phosphorylase deficiency with fatal course in two sisters. Eur J Pediatr 169(3):311–314PubMedCrossRefGoogle Scholar
  11. 11.
    Markert ML (1991) Purine nucleoside phosphorylase deficiency. Immunodefic Rev 3(1):45–81PubMedGoogle Scholar
  12. 12.
    Kalman L, Lindegren ML, Kobrynski L, Vogt R, Hannon H, Howard JT, Buckley R (2004) Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review. Genet Med 6(1):16–26PubMedCrossRefGoogle Scholar
  13. 13.
    Roifman CM (2005) Studies of patients’ thymi aid in the discovery and characterization of immunodeficiency in humans. Immunol Rev 203:143–155PubMedCrossRefGoogle Scholar
  14. 14.
    Shiow LR, Roadcap DW, Paris K, Watson SR, Grigorova IL, Lebet T, An J, Xu Y, Jenne CN, Foger N, Sorensen RU, Goodnow CC, Bear JE, Puck JM, Cyster JG (2008) The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol 9(11):1307–1315PubMedCrossRefGoogle Scholar
  15. 15.
    Wada T, Yasui M, Toma T, Nakayama Y, Nishida M, Shimizu M, Okajima M, Kasahara Y, Koizumi S, Inoue M, Kawa K, Yachie A (2008) Detection of T lymphocytes with a second-site mutation in skin lesions of atypical X-linked severe combined immunodeficiency mimicking Omenn syndrome. Blood 112(5):1872–1875PubMedCrossRefGoogle Scholar
  16. 16.
    Markert ML, Devlin BH, Chinn IK, McCarthy EA (2009) Thymus transplantation in complete DiGeorge anomaly. Immunol Res 44(1–3):61–70PubMedCrossRefGoogle Scholar
  17. 17.
    Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Hammartrom L, Nonoyama S, Ochs HD, Puck J, Roifman C, Seger R, Wedgwood J (2009) Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 124(6):1161–1178PubMedCrossRefGoogle Scholar
  18. 18.
    Sauer AV, Aiuti A (2009) New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr Opin Allergy Clin Immunol 9(6):496–502PubMedCrossRefGoogle Scholar
  19. 19.
    Booth C, Gaspar HB (2009) Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 3:349–358PubMedGoogle Scholar
  20. 20.
    Aiuti A, Brigida I, Ferrua F, Cappelli B, Chiesa R, Marktel S, Roncarolo MG (2009) Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immunol Res 44(1–3):150–159PubMedCrossRefGoogle Scholar
  21. 21.
    Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360(5):447–458PubMedCrossRefGoogle Scholar
  22. 22.
    Honig M, Albert MH, Schulz A, Sparber-Sauer M, Schutz C, Belohradsky B, Gungor T, Rojewski MT, Bode H, Pannicke U, Lippold D, Schwarz K, Debatin KM, Hershfield MS, Friedrich W (2007) Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 109(8):3595–3602PubMedCrossRefGoogle Scholar
  23. 23.
    Buckley RH (2004) A historical review of bone marrow transplantation for immunodeficiencies. J Allergy Clin Immunol 113(4):793–800PubMedCrossRefGoogle Scholar
  24. 24.
    Broides A, Yang W, Conley ME (2006) Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol 118(2–3):195–200PubMedCrossRefGoogle Scholar
  25. 25.
    Myers LA, Patel DD, Puck JM, Buckley RH (2002) Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99(3):872–878PubMedCrossRefGoogle Scholar
  26. 26.
    Railey MD, Lokhnygina Y, Buckley RH (2009) Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr 155(6):834–840.e831PubMedCrossRefGoogle Scholar
  27. 27.
    Qasim W, Gaspar HB, Thrasher AJ (2009) Progress and prospects: gene therapy for inherited immunodeficiencies. Gene Ther 16(11):1285–1291PubMedCrossRefGoogle Scholar
  28. 28.
    Buckley RH (2000) Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol Res 22(2–3):237–251PubMedCrossRefGoogle Scholar
  29. 29.
    Hershfield MS (2000) Immunodeficiency caused by adenosine deaminase deficiency. Immunol Allergy Clin North Am 20:161–175CrossRefGoogle Scholar
  30. 30.
    Elder ME, Lin D, Clever J, Chan AC, Hope TJ, Weiss A, Parslow TG (1994) Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 264(5165):1596–1599PubMedCrossRefGoogle Scholar
  31. 31.
    Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ (1993) Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73(1):147–157PubMedCrossRefGoogle Scholar
  32. 32.
    Pannicke U, Honig M, Hess I, Friesen C, Holzmann K, Rump EM, Barth TF, Rojewski MT, Schulz A, Boehm T, Friedrich W, Schwarz K (2009) Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nat Genet 41(1):101–105PubMedCrossRefGoogle Scholar
  33. 33.
    Cederbaum SD, Kaitila I, Rimoin DL, Stiehm ER (1976) The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency. J Pediatr 89(5):737–742PubMedCrossRefGoogle Scholar
  34. 34.
    Shovlin CL, Simmonds HA, Fairbanks LD, Deacock SJ, Hughes JM, Lechler RI, Webster AD, Sun XM, Webb JC, Soutar AK (1994) Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. J Immunol 153(5):2331–2339PubMedGoogle Scholar
  35. 35.
    Hirschhorn R, Ellenbogen A (1986) Genetic heterogeneity in adenosine deaminase (ADA) deficiency: five different mutations in five new patients with partial ADA deficiency. Am J Hum Genet 38(1):13–25PubMedGoogle Scholar
  36. 36.
    Hirschhorn R, Yang DR, Puck JM, Huie ML, Jiang CK, Kurlandsky LE (1996) Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet 13(3):290–295PubMedCrossRefGoogle Scholar
  37. 37.
    Albuquerque W, Gaspar HB (2004) Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr 144(2):278–280PubMedCrossRefGoogle Scholar
  38. 38.
    Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB (2001) Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr 139(1):44–50PubMedCrossRefGoogle Scholar
  39. 39.
    Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, Fasth A, Heilmann C, Wulffraat N, Seger R, Blanche S, Friedrich W, Abinun M, Davies G, Bredius R, Schulz A, Landais P, Fischer A (2003) Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet 361(9357):553–560PubMedCrossRefGoogle Scholar
  40. 40.
    Booth C, Hershfield M, Notarangelo L, Buckley R, Hoenig M, Mahlaoui N, Cavazzana-Calvo M, Aiuti A, Gaspar HB (2007) Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 123(2):139–147PubMedCrossRefGoogle Scholar
  41. 41.
    Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS (1992) IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89(5):1643–1651PubMedCrossRefGoogle Scholar
  42. 42.
    Hershfield MS (1998) Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin Hematol 35(4):291–298PubMedGoogle Scholar
  43. 43.
    Eyerich K, Foerster S, Rombold S, Seidl HP, Behrendt H, Hofmann H, Ring J, Traidl-Hoffmann C (2008) Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 128(11):2640–2645PubMedCrossRefGoogle Scholar
  44. 44.
    Glocker E, Grimbacher B (2010) Chronic mucocutaneous candidiasis and congenital susceptibility toCandida. Curr Opin Allergy Clin Immunol 10(6):542–550PubMedCrossRefGoogle Scholar
  45. 45.
    Halonen M, Eskelin P, Myhre AG, Perheentupa J, Husebye ES, Kampe O, Rorsman F, Peltonen L, Ulmanen I, Partanen J (2002) AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab 87(6):2568–2574PubMedCrossRefGoogle Scholar
  46. 46.
    Fischer A, Ballet JJ, Griscelli C (1978) Specific inhibition of in vitro Candida-induced ­lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis. J Clin Invest 62(5):1005–1013PubMedCrossRefGoogle Scholar
  47. 47.
    Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, Masson C, Toth B, Flatot J, Migaud M, Chrabieh M, Kochetkov T, Bolze A, Borghesi A, Toulon A, Hiller J, Eyerich S, Eyerich K, Gulacsy V, Chernyshova L, Chernyshov V, Bondarenko A, Grimaldo RM, Blancas-Galicia L, Beas IM, Roesler J, Magdorf K, Engelhard D, Thumerelle C, Burgel PR, Hoernes M, Drexel B, Seger R, Kusuma T, Jansson AF, Sawalle-Belohradsky J, Belohradsky B, Jouanguy E, Bustamante J, Bue M, Karin N, Wildbaum G, Bodemer C, Lortholary O, Fischer A, Blanche S, Al-Muhsen S, Reichenbach J, Kobayashi M, Rosales FE, Lozano CT, Kilic SS, Oleastro M, Etzioni A, Traidl-Hoffmann C, Renner ED, Abel L, Picard C, Marodi L, Boisson-Dupuis S, Puel A, Casanova JL (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208(8):1635–1648PubMedCrossRefGoogle Scholar
  48. 48.
    Kato M, Kimura H, Seki M, Shimada A, Hayashi Y, Morio T, Kumaki S, Ishida Y, Kamachi Y, Yachie A (2006) Omenn syndrome – review of several phenotypes of Omenn syndrome and RAG1/RAG2 mutations in Japan. Allergol Int 55(2):115–119PubMedCrossRefGoogle Scholar
  49. 49.
    Ohm-Laursen L, Nielsen C, Fisker N, Lillevang ST, Barington T (2008) Lack of nonfunctional B-cell receptor rearrangements in a patient with normal B cell numbers despite partial RAG1 deficiency and atypical SCID/Omenn syndrome. J Clin Immunol 28(5):588–592PubMedCrossRefGoogle Scholar
  50. 50.
    Bieber T, Novak N (2009) Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma Rep 9(4):291–294PubMedCrossRefGoogle Scholar
  51. 51.
    Minegishi Y, Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, Agematsu K, Yamada M, Kawamura N, Ariga T, Tsuge I, Karasuyama H (2009) Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 206(6):1291–1301PubMedCrossRefGoogle Scholar
  52. 52.
    Renner ED, Hartl D, Rylaarsdam S, Young ML, Monaco-Shawver L, Kleiner G, Markert ML, Stiehm ER, Belohradsky BH, Upton MP, Torgerson TR, Orange JS, Ochs HD (2009) Comel-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 124(3):536–543PubMedCrossRefGoogle Scholar
  53. 53.
    Villa A, Notarangelo LD, Roifman CM (2008) Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol 122(6):1082–1086PubMedCrossRefGoogle Scholar
  54. 54.
    Turul T, Tezcan I, Artac H, de Bruin-Versteeg S, Barendregt BH, Reisli I, Sanal O, van Dongen JJ, van der Burg M (2009) Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. Eur J Pediatr 168(1):87–93PubMedCrossRefGoogle Scholar
  55. 55.
    Appleton AL, Curtis A, Wilkes J, Cant AJ (1994) Differentiation of materno-fetal GVHD from Omenn’s syndrome in pre-BMT patients with severe combined immunodeficiency. Bone Marrow Transplant 14(1):157–159PubMedGoogle Scholar
  56. 56.
    Marrella V, Poliani PL, Casati A, Rucci F, Frascoli L, Gougeon ML, Lemercier B, Bosticardo M, Ravanini M, Battaglia M, Roncarolo MG, Cavazzana-Calvo M, Facchetti F, Notarangelo LD, Vezzoni P, Grassi F, Villa A (2007) A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest 117(5):1260–1269PubMedCrossRefGoogle Scholar
  57. 57.
    Rosen FS, Eibl MM, Roifman C, et al. (1999) Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol 118 Suppl 1:1–28Google Scholar
  58. 58.
    Fischer A, Le Deist F, Hacein-Bey-Abina S, Andre-Schmutz I, Basile Gde S, de Villartay JP, Cavazzana-Calvo M (2005) Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 203:98–109PubMedCrossRefGoogle Scholar
  59. 59.
    Neves I Jr, Morgado M (2000) Immunological evaluation of human immunodeficiency virus infected individuals by flow cytometry. Mem Inst Oswaldo Cruz 95(3):393–400PubMedCrossRefGoogle Scholar
  60. 60.
    Elder ME (1997) SCID due to ZAP-70 deficiency. J Pediatr Hematol Oncol 19(6):546–550PubMedCrossRefGoogle Scholar
  61. 61.
    Zimmer J, Andres E, Donato L, Hanau D, Hentges F, de la Salle H (2005) Clinical and immunological aspects of HLA class I deficiency. QJM 98(10):719–727PubMedCrossRefGoogle Scholar
  62. 62.
    Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V (2000) TAP deficiency syndrome. Clin Exp Immunol 121(2):173–178PubMedCrossRefGoogle Scholar
  63. 63.
    Hoffman GS, Gross WL (2002) Wegener’s granulomatosis: clinical aspects. In: Hoffman GS, Weyand CM (eds) Inflammatory diseases of blood vessels. Marcel Dekker, New York, pp 381–397Google Scholar
  64. 64.
    Villa-Forte A, de la Salle H, Fricker D, Hentges F, Zimmer J (2008) HLA class I deficiency syndrome mimicking Wegener’s granulomatosis. Arthritis Rheum 58(8):2579–2582PubMedCrossRefGoogle Scholar
  65. 65.
    Cunningham-Rundles C (1989) Clinical and immunologic analyses of 103 patients with ­common variable immunodeficiency. J Clin Immunol 9(1):22–33PubMedCrossRefGoogle Scholar
  66. 66.
    Hitzig WH, Seger RA (1983) Chronic granulomatous disease, a heterogeneous syndrome. Hum Genet 64(3):207–215PubMedCrossRefGoogle Scholar
  67. 67.
    Liese JG, Jendrossek V, Jansson A, Petropoulou T, Kloos S, Gahr M, Belohradsky BH (1996) Chronic granulomatous disease in adults. Lancet 347(8996):220–223PubMedCrossRefGoogle Scholar
  68. 68.
    Mechanic LJ, Dikman S, Cunningham-Rundles C (1997) Granulomatous disease in common variable immunodeficiency. Ann Intern Med 127(8 Pt 1):613–617PubMedGoogle Scholar
  69. 69.
    Koch J, Tampe R (2006) The macromolecular peptide-loading complex in MHC class I-dependent antigen presentation. Cell Mol Life Sci 63(6):653–662PubMedCrossRefGoogle Scholar
  70. 70.
    Cabrera CM (2007) The double role of the endoplasmic reticulum chaperone tapasin in peptide optimization of HLA class I molecules. Scand J Immunol 65(6):487–493PubMedCrossRefGoogle Scholar
  71. 71.
    Wright CA, Kozik P, Zacharias M, Springer S (2004) Tapasin and other chaperones: models of the MHC class I loading complex. Biol Chem 385(9):763–778PubMedCrossRefGoogle Scholar
  72. 72.
    Matamoros N, Mila J, Llano M, Balas A, Vicario JL, Pons J, Crespi C, Martinez N, Iglesias-Alzueta J, Lopez-Botet M (2001) Molecular studies and NK cell function of a new case of TAP2 homozygous human deficiency. Clin Exp Immunol 125(2):274–282PubMedCrossRefGoogle Scholar
  73. 73.
    Plebani A, Monafo V, Cattaneo R, Carella G, Brugnoni D, Facchetti F, Battocchio S, Meini A, Notarangelo LD, Duse M, Ugazio AG (1996) Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. J Am Acad Dermatol 35(5 Pt 2):814–818PubMedCrossRefGoogle Scholar
  74. 74.
    Klein C, Lisowska-Grospierre B, LeDeist F, Fischer A, Griscelli C (1993) Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 123(6):921–928PubMedCrossRefGoogle Scholar
  75. 75.
    Wolf HM, Thon V, Gulle H, Lechleitner S, Eibl MM, Petzelbauer P (2001) Residual expression of functional MHC class II molecules in twin brothers with MHC class II deficiency is cell type specific. Br J Haematol 115(2):460–471PubMedCrossRefGoogle Scholar
  76. 76.
    Krawczyk M, Reith W (2006) Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Tissue Antigens 67(3):183–197PubMedCrossRefGoogle Scholar
  77. 77.
    Reith W, Mach B (2001) The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19:331–373PubMedCrossRefGoogle Scholar
  78. 78.
    Gennery AR, Cant AJ (2001) Diagnosis of severe combined immunodeficiency. J Clin Pathol 54(3):191–195PubMedCrossRefGoogle Scholar
  79. 79.
    Gennery AR, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, Fischer A, Landais P, Cavazzana-Calvo M, Friedrich W, Fasth A, Wulffraat NM, Matthes-Martin S, Bensoussan D, Bordigoni P, Lange A, Pagliuca A, Andolina M, Cant AJ, Davies EG (2004) Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993–2002. Blood 103(3):1152–1157PubMedCrossRefGoogle Scholar
  80. 80.
    Notarangelo LD, Lanzi G, Peron S, Durandy A (2006) Defects of class-switch recombination. J Allergy Clin Immunol 117(4):855–864PubMedCrossRefGoogle Scholar
  81. 81.
    Notarangelo LD, Lanzi G, Toniati P, Giliani S (2007) Immunodeficiencies due to defects of class-switch recombination. Immunol Res 38(1–3):68–77PubMedCrossRefGoogle Scholar
  82. 82.
    Klein C, Cavazzana-Calvo M, Le Deist F, Jabado N, Benkerrou M, Blanche S, Lisowska-Grospierre B, Griscelli C, Fischer A (1995) Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood 85(2):580–587PubMedGoogle Scholar
  83. 83.
    Saleem MA, Arkwright PD, Davies EG, Cant AJ, Veys PA (2000) Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child 83(4):356–359PubMedCrossRefGoogle Scholar
  84. 84.
    Barrett DJ, Ammann AJ, Wara DW, Cowan MJ, Fisher TJ, Stiehm ER (1981) Clinical and immunologic spectrum of the DiGeorge syndrome. J Clin Lab Immunol 6(1):1–6PubMedGoogle Scholar
  85. 85.
    Sullivan KE (2004) The clinical, immunological, and molecular spectrum of chromosome 22q11.2 deletion syndrome and DiGeorge syndrome. Curr Opin Allergy Clin Immunol 4(6):505–512PubMedCrossRefGoogle Scholar
  86. 86.
    McLean-Tooke A, Spickett GP, Gennery AR (2007) Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome. Scand J Immunol 66(1):1–7PubMedCrossRefGoogle Scholar
  87. 87.
    Rezaei N, Aghamohammadi A, Notarangelo LD (2008) Primary immunodeficiency diseases: definition, diagnosis and management, vol 1. Springer, Berlin HeidelbergCrossRefGoogle Scholar
  88. 88.
    Smith CA, Driscoll DA, Emanuel BS, McDonald-McGinn DM, Zackai EH, Sullivan KE (1998) Increased prevalence of immunoglobulin A deficiency in patients with the chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Diagn Lab Immunol 5(3):415–417PubMedGoogle Scholar
  89. 89.
    Sorensen RU, Moore C (2000) Antibody deficiency syndromes. Pediatr Clin North Am 47(6):1225–1252PubMedCrossRefGoogle Scholar
  90. 90.
    Conley ME, Beckwith JB, Mancer JF, Tenckhoff L (1979) The spectrum of the DiGeorge syndrome. J Pediatr 94(6):883–890PubMedCrossRefGoogle Scholar
  91. 91.
    Conley ME, Notarangelo LD, Etzioni A (1999) Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93(3):190–197PubMedCrossRefGoogle Scholar
  92. 92.
    de Vries E (2006) Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists. Clinical Working Party of the European Society for Immunodeficiencies (ESID). Clin Exp Immunol 145(2):204–214Google Scholar
  93. 93.
    Gennery AR, Barge D, O’Sullivan JJ, Flood TJ, Abinun M, Cant AJ (2002) Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. Arch Dis Child 86(6):422–425PubMedCrossRefGoogle Scholar
  94. 94.
    Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, Sediva A, Marrella V, Villa A, Fischer A, Notarangelo LD, Badolato R (2005) AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest 115(3):728–732PubMedGoogle Scholar
  95. 95.
    Lawrence S, McDonald-McGinn DM, Zackai E, Sullivan KE (2003) Thrombocytopenia in patients with chromosome 22q11.2 deletion syndrome. J Pediatr 143(2):277–278PubMedCrossRefGoogle Scholar
  96. 96.
    Davies JK, Telfer P, Cavenagh JD, Foot N, Neat M (2003) Autoimmune cytopenias in the 22q11.2 deletion syndrome. Clin Lab Haematol 25(3):195–197PubMedCrossRefGoogle Scholar
  97. 97.
    Sullivan KE, McDonald-McGinn DM, Driscoll DA, Zmijewski CM, Ellabban AS, Reed L, Emanuel BS, Zackai EH, Athreya BH, Keenan G (1997) Juvenile rheumatoid arthritis-like polyarthritis in chromosome 22q11.2 deletion syndrome (DiGeorge anomalad/velocardiofacial syndrome/conotruncal anomaly face syndrome). Arthritis Rheum 40(3):430–436PubMedCrossRefGoogle Scholar
  98. 98.
    Brown JJ, Datta V, Browning MJ, Swift PG (2004) Graves’ disease in DiGeorge syndrome: patient report with a review of endocrine autoimmunity associated with 22q11.2 deletion. J Pediatr Endocrinol Metab 17(11):1575–1579PubMedCrossRefGoogle Scholar
  99. 99.
    Carotti A, Digilio MC, Piacentini G, Saffirio C, Di Donato RM, Marino B (2008) Cardiac defects and results of cardiac surgery in 22q11.2 deletion syndrome. Dev Disabil Res Rev 14(1):35–42PubMedCrossRefGoogle Scholar
  100. 100.
    Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC (2007) Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood 109(10):4539–4547PubMedCrossRefGoogle Scholar
  101. 101.
    Matsumoto T, Amamoto N, Kondoh T, Nakayama M, Takayanagi T, Tsuji Y (1998) Complete-type DiGeorge syndrome treated by bone marrow transplantation. Bone Marrow Transplant 22(9):927–930PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Francisco A. Bonilla
    • 1
    • 2
  • Isil B. Barlan
    • 3
  • Elif Aydiner
    • 3
  • Waleed Al-Herz
    • 4
  • Martha M. Eibl
    • 5
  • Teresa Espanol
    • 6
  • Andrea Martín
    • 7
  • László Maródi
    • 8
  • Shabnam Pourhamdi
    • 9
  • Pere Soler-Palacín
    • 7
  • Hermann M. Wolf
    • 5
  • Asghar Aghamohammadi
    • 10
  1. 1.Division of ImmunologyBoston Children’s HospitalBostonUSA
  2. 2.Department of PediatricsHarvard Medical SchoolBostonUSA
  3. 3.Division of Pediatric Allergy/ImmunologyMarmara UniversityIstanbulTurkey
  4. 4.Department of PediatricsKuwait UniversityKuwaitKuwait
  5. 5.Department of PediatricsImmunological Outpatient Clinic,Biomedical Research InstituteViennaAustria
  6. 6.Department of Immunology and Immunodeficiencies, School of MedicineUniversity Hospital Vall d’HebronBarcelonaSpain
  7. 7.Pediatric Infectious Diseases and Immunodeficiencies UnitVall d’Hebron University HospitalBarcelonaSpain
  8. 8.Department of Infectious and Pediatric ImmunologyMedical and Health Science Center, University of DebrecenDebrecenHungary
  9. 9.Department of PediatricsResearch Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical SciencesTehranIran
  10. 10.Division of Clinical Immunology and AllergyResearch Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical SciencesTehranIran

Personalised recommendations